Creating a global CDMO player, ROIS, through the acquisition of an injectable drug product manufacturing site in Phoenix, Arizona (USA)

Disclaimer

- This Presentation has been prepared by Laboratorios Farmacéuticos ROVI, S.A. (the “Company”) and comprises the slides for a presentation concerning the Company and its subsidiaries (the “Group”). For the purposes of this disclaimer, “Presentation” means this document, its contents or any part of it, any oral presentation, any question and answer session and any written or oral material discussed or distributed during the Presentation or otherwise in connection with it.
- This Presentation does not constitute or form part of, and should not be construed as, any offer to sell or issue or invitation to purchase or subscribe for, or any solicitation of any offer to purchase or subscribe for, any securities of the Company, neither shall it or any part of it nor the fact of its distribution form the basis of, or be relied on in connection with, any contract or investment decision.
- The information contained in this Presentation does not purport to be comprehensive. Neither the Company, nor its respective subsidiaries or affiliates, nor its or their respective directors, officers, employees, advisers or agents accepts any responsibility or liability whatsoever for, or makes any representation or warranty, express or implied, as to the truth, fullness, accuracy or completeness of the information in this Presentation (or whether any information has been omitted from the Presentation) or any other information relating to the Group, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available or for any loss howsoever arising from any use of this Presentation or its contents or otherwise arising in connection herewith. Each of such persons accordingly disclaims all and any liability whatsoever, whether arising in tort, contract or otherwise in respect of this Presentation or any such information.
- The information in this Presentation may include forward-looking statements, which are based on current expectations, projections and assumptions about future events. These forward-looking statements as well as those included in any other information discussed in the Presentation have not been reviewed or audited by the Company’s auditors nor by any independent expert and are subject to known or unknown risks, uncertainties and assumptions about the Group and its investments, including, among other things, the development of its business, its growth plan, trends in its operating industry, its future capital expenditures and acquisitions. In the light of these risks, uncertainties and assumptions, the events in the forward-looking statements may not occur and actual results, performance or achievements may materially differ from any future results, performance or achievements that may be expressed or implied in this Presentation.
- No representation or warranty is made that any forward-looking statement will come to pass. Forward-looking statements speak as of the date of this Presentation and no one undertakes to publicly update or revise any such forward-looking statement, whether as a result of new information, future events or otherwise. Accordingly, undue reliance should not be placed on any forward-looking statement contained in this Presentation.
- To the extent available, the industry, market and competitive position data contained in this Presentation come from official or third-party sources. Third party industry publications, studies and surveys generally state that the data contained therein have been obtained from sources believed to be reliable, but that there is no guarantee of the accuracy or completeness of such data. While the Company reasonably believes that each of these publications, studies and surveys has been prepared by a reputable source, the Company has not independently verified the data contained therein. In addition, certain of the industry, market and competitive position data contained in this Presentation come from the Company’s own internal research and estimates based on the knowledge and experience of the Company’s management in the markets in which the Group operates. While the Company reasonably believes that such research and estimates are reasonable and reliable, they, and their underlying methodology and assumptions, have not been verified by any independent source for accuracy or completeness and are subject to change. Accordingly, undue reliance should not be placed on any of the industry, market or competitive position data contained in this Presentation.
- This Presentation may also include certain alternative performance measures ("APMs") that have not been prepared under IFRS-EU and have not been reviewed or audited by the Company’s auditors nor by any independent expert. Moreover, the way the Group defines and calculates these measures may differ to the way similar measures are calculated by other companies. Accordingly, they may not be comparable.
- Certain financial and statistical information contained in this Presentation is subject to rounding adjustments. Accordingly, any discrepancies between the totals and the sums of the amounts listed are due to rounding. Certain financial information and operating data relating to the Company contained in this Presentation has not been audited and in some cases is based on management information and estimates, and is subject to change.
- No reliance may or should be placed by any person for any purposes whatsoever on this Presentation, or on its completeness, accuracy or fairness. The information in this Presentation is in summary draft form for discussion purposes only. The information and opinions contained in this Presentation are provided as at the date of the Presentation and are subject to verification, correction, completion and change without notice. In giving this Presentation, neither the Company, nor its subsidiaries or affiliates, nor its or their respective directors, officers, employees, advisers or agents, undertakes any obligation to amend, correct or update this Presentation or to provide the recipient with access to any additional information that may arise in connection herewith.

Overview of Phoenix site (1/2)

Acquisition of a sterile fill&finish drug product manufacturing and packaging site located in Phoenix, Arizona (USA)

Well-trained and highly experienced workforce

~$100m CAPEX invested since 2021 into the site

Total facility size of ~34k m^2, situated on ~80k m^2 of land

State-of-the-art site, including a cytotoxic area, approved by the FDA[1], EMA[2], Japanese agency, among others

New optima pre-filled syringe (PFS) filling line with isolator technology to be installed in a segregated area in 2027, adding a capacity of 65m-70m PFS

Bristol Myers Squibb™

$250m 5-year initial term supply agreement

1. FDA: U.S. Food and Drug Administration
2. EMA: European Medicines Agency

Overview of Phoenix site (2/2)

- **New Shell provides ample expansion space to build a segregated area for manufacturing biologic products**
- New optima pre-filled syringe (PFS) filling line with isolator technology to be installed



- **Warehouse space**

- **Building A houses all current manufacturing and laboratory facilities**
- Current manufacture

Transaction allows for continued strong manufacturing of essential medicines in US soil

- High-potent cytotoxic products
- Obesity products
- Vaccines
- Biosimilars
- Monoclonal antibodies
- Antibody-Drug Conjugate (ADCs)

Phoenix: A great place to do business

+$4B
Capital investments 2019-2023[1]

+550k m²
Primary Facilities Square Footage 2019-2023[1]

+10K
New bioscience & HC Jobs 2019-2023[1]

$85k
Average Household Income[2]

35.4
Median Age[2]

ROIS Phoenix

- Vials and PFS
- Packaging
- High-potent OEB5[3] product expertise

Located two blocks away from **Interstate 10** and **Loop 202**

Phoenix is the 5th largest city in the nation and the fastest growing 5 years in a row[1;4]

1. Source: AZ Big Media. (2023, September 19).
2. Source: U.S. Census Bureau. (2024). Phoenix city, Arizona - Census Bureau Profile.
3. OEB5 = Occupational Exposure Band 5
4. Between 2016 and 2020.

Strategically significant acquisition

A key step toward achieving our vision to be one of the top CDMOs worldwide in high value added injectables in PFS, cartridges and vials

Broadens ROIS's global manufacturing network by adding a new state-of-the-art site, enhancing injectable capacity, strengthening partnerships and supporting the supply of medicines

Expands ROIS's high value injectable capacity to develop and manufacture injectable medicines at commercial scale, enabling the company to serve pharmaceutical and biotech customers directly in US soil while continuing to build on its strong European base

Enhances ROIS's know-how and capacity for manufacturing high-potent OEB5 cytotoxic injectable products

Strengthens ROIS's commitment to innovation and investment in cutting-edge facilities and equipment

Scales ROIS's US sales team to capture new growth opportunities

Transaction Key Terms

Acquisition structure and price	• ROVI to acquire via its subsidiary ROIS Phoenix, Inc., the facilities located in Phoenix from Bristol Myers Squibb and its relevant Affiliates (“BMS”) for a price which is not material for ROVI
5-year supply agreement	• ROVI has entered into a Toll Manufacturing Agreement with BMS, which regulates the conditions under which ROIS Phoenix, Inc. (the Buyer) will continue to manufacture for BMS at the facilities, with the necessary personnel as of the closing date to enable its operability. The agreement has an initial term of five years from the closing of the Transaction and provides for a minimum payment to the Buyer of $50m for each year of the contract
Completion considerations	• The acquisition is subject to customary closing conditions, including obtaining regulatory approvals, and no material adverse change occurring prior to the completion of the transaction • Estimated closing date: H1 2026

Our plans for ROIS Phoenix, Inc.

Strategic assessment for the mid-term future of the Phoenix site



Thanks to our dedicated team of ROIS Phoenix employees, we are strongly equipped to drive the continued growth of our facility

ROIS as a CDMO global player

ROIS

Welcome to ROIS!



Our customers rely on us for our scale, speed, and quality

New brand as a complementary tool alongside the strategy of enlarging our sales force team and expanding our marketing activities to increase brand awareness in US and EU

ROIS EU: CDMO services

ROIS US: CDMO services



ROIS Granada

API Biologics Manufacturing site

ROIS Julián Camarillo (Madrid)

Fill and finish of PFS and cartridges

ROIS San Sebastián de los Reyes

Fill and finish of PFS, cartridges and vials

ROIS Alcalá de Henares

Our center of excellence for injectable packaging

ROIS Phoenix

Manufacture, fill&finish and packaging

API manufacturing

Fill and finish of injectables

PFS · Vials · RTU[1] Cartridges

Packaging and manufacture of solid forms

Packaging · Pens · Auto injectors · Solids

Fill and finish of injectables High potent expertise

PFS · Vials · Packaging

1. Ready-to-use

Increasing capacities across CDMO network to drive long-term growth and capture new opportunities

Key metrics post ROIS Phoenix integration

	2024	2026E Pre ROIS Phoenix integration	2027E Post ROIS Phoenix integration
CDMO sites (#)	4	4	5
Aseptic filling lines (#)	11	12[1]	14
Packaging lines (#)	15	15	16

Capacity evolution post ROIS Phoenix integration (m#)



1. Increase due to 2 new lines (1 substitutes a current operating line)
2. Both PFS and vials figures include two combo lines that can produce PFS or vials
3. Both PFS and cartridges figures include two combo lines that can produce PFS or cartridges
4. New vial capacity has not been included.

Site pictures

Thank you!